Trillium Therapeutics Inc

Change company Symbol lookup

Select an option...

TRIL Trillium Therapeutics Inc

CLM Cornerstone Strategic Value Fund

HRC Hill-Rom Holdings Inc

QRTEB Qurate Retail Inc

GGN GAMCO Global Gold, Natural Resources & Income Trust

GGN GAMCO Global Gold, Natural Resources & Income Trust

GFY Western Asset Variable Rate Strategic Fund Inc

GE General Electric Co

GDXJ VanEck Vectors Junior Gold Miners ETF

GDX VanEck Vectors Gold Miners ETF

Go

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.